Cytek Biosciences (CTKB) Gross Profit (2020 - 2026)

Cytek Biosciences has reported Gross Profit for 7 years, with the latest figure at $21.3 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit rose 5.44% year-over-year to $21.3 million; the trailing twelve-month figure through Mar 2026 stood at $105.6 million (down 2.49% YoY), and the FY2025 full-year result was $104.5 million, down 5.98% from the prior year.
• Gross Profit for Q1 2026 stood at $21.3 million, down from $32.9 million in the prior quarter.
• The five-year high for Gross Profit was $33.7 million in Q4 2024, with the low at $20.2 million in Q1 2025.
• Historically, Gross Profit has averaged $26.3 million across 5 years, with a median of $26.9 million in 2022.
• Annual changes were most pronounced in 2022 — Gross Profit soared 39.29% — and 2025, when it declined 12.41%.
• Cytek Biosciences' Gross Profit stood at $29.4 million in 2022, then climbed by 12.51% to $33.0 million in 2023, then gained by 1.83% to $33.7 million in 2024, then retreated by 2.28% to $32.9 million in 2025, then slumped by 35.37% to $21.3 million in 2026.
• The last three Gross Profit figures came in at $21.3 million (Q1 2026), $32.9 million (Q4 2025), and $27.6 million (Q3 2025), per Business Quant data.